Search research articles
Contact Us
Filters
Showing results (31-40 of 228) with videos related to
Page
of 23
Sort By:
Biologics : Targets & Therapy
|
August 27, 2009
Trastuzumab in the management of early and advanced stage breast cancer
Rupert Bartsch, Catharina Wenzel, Guenther G Steger
The Lancet. Oncology
|
December 20, 2014
CDK4/6 inhibitors in luminal breast cancer
Michael Gnant, Guenther G Steger, Rupert Bartsch
The Lancet. Oncology
|
August 15, 2015
Bevacizumab: no comeback in early breast cancer?
Rupert Bartsch, Michael Gnant, Guenther G Steger
The Lancet. Oncology
|
December 28, 2020
Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
Rupert Bartsch, Christoph Minichsdorfer, Cornelia Kolberg-Liedtke
Wiener Klinische Wochenschrift
|
July 31, 2025
Vanessa Castagnaviz, Anna Fenzl, Michael Gnant, et al.
Anticancer Research
|
August 5, 2006
Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer
Rupert Bartsch, Stefan Woehrer, Markus Raderer, et al.
Memo
|
May 9, 2020
Circumnavigating the challenges of COVID-19 in oncology
Thorsten Fuereder, Eberhard Gunsilius, Rupert Bartsch, et al.
Wiener Klinische Wochenschrift
|
September 22, 2025
Vanessa Castagnaviz, Anna Fenzl, Michael Gnant, et al.
Breast Care (Basel, Switzerland)
|
December 14, 2011
Opinions on the ASCO 2011 Annual Meeting
Rupert Bartsch, Peter C Dubsky, Sibylle Loibl, et al.
Breast Care (Basel, Switzerland)
|
July 23, 2011
Breast Cancer: Rank Ligand Inhibition
Rupert Bartsch, Guenther G Steger, Michael Gnant, et al.
Page
of 23
Search research articles
Search
Showing results (31-40 of 228) with videos related to
Sort By:
Page
of 23
Biologics : Targets & Therapy
|
August 27, 2009
Trastuzumab in the management of early and advanced stage breast cancer
Rupert Bartsch, Catharina Wenzel, Guenther G Steger
The Lancet. Oncology
|
December 20, 2014
CDK4/6 inhibitors in luminal breast cancer
Michael Gnant, Guenther G Steger, Rupert Bartsch
The Lancet. Oncology
|
August 15, 2015
Bevacizumab: no comeback in early breast cancer?
Rupert Bartsch, Michael Gnant, Guenther G Steger
The Lancet. Oncology
|
December 28, 2020
Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
Rupert Bartsch, Christoph Minichsdorfer, Cornelia Kolberg-Liedtke
Wiener Klinische Wochenschrift
|
July 31, 2025
Vanessa Castagnaviz, Anna Fenzl, Michael Gnant, et al.
Anticancer Research
|
August 5, 2006
Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer
Rupert Bartsch, Stefan Woehrer, Markus Raderer, et al.
Memo
|
May 9, 2020
Circumnavigating the challenges of COVID-19 in oncology
Thorsten Fuereder, Eberhard Gunsilius, Rupert Bartsch, et al.
Wiener Klinische Wochenschrift
|
September 22, 2025
Vanessa Castagnaviz, Anna Fenzl, Michael Gnant, et al.
Breast Care (Basel, Switzerland)
|
December 14, 2011
Opinions on the ASCO 2011 Annual Meeting
Rupert Bartsch, Peter C Dubsky, Sibylle Loibl, et al.
Breast Care (Basel, Switzerland)
|
July 23, 2011
Breast Cancer: Rank Ligand Inhibition
Rupert Bartsch, Guenther G Steger, Michael Gnant, et al.
Page
of 23